Serum and plasma are both derived from whole blood, and both are widely used in biomarker research — but they are not interchangeable. The choice between them is a scientific decision with procurement consequences, and it needs to be made before collection begins. Switching after the fact means recollecting.
What Makes Them Different
The difference comes down to one step: clotting.
Plasma is collected by drawing blood into a tube containing an anticoagulant, then centrifuging to remove cells. The liquid fraction — plasma — retains fibrinogen, coagulation factors, and all other proteins and analytes present in circulating blood at the time of collection. It represents the most intact snapshot of what was in the bloodstream.
Serum is collected without anticoagulant. Blood is allowed to clot, typically for 30–60 minutes at room temperature, and then centrifuged. The clot pulls fibrinogen and coagulation factors out of the liquid fraction, along with platelets and some other proteins. What remains — serum — is a clarified, protein-rich fluid that is depleted of clotting factors relative to plasma.
The clotting process also causes platelets to degranulate, releasing their contents — growth factors, cytokines, and other signaling proteins — into the serum. This means serum contains higher concentrations of certain analytes than plasma does, which is advantageous for some assays and a confound for others.
Tube Selection
The anticoagulant used in plasma collection is not a trivial choice — different anticoagulants suit different downstream applications:
EDTA tubes (purple top) are the most common choice for plasma in biomarker research. EDTA chelates calcium, preventing clotting without adding exogenous proteins or altering most analyte concentrations. It is the standard for liquid biopsy (cfDNA/ctDNA), most proteomics workflows, and general biomarker panels. EDTA is not compatible with some enzymatic assays.
Heparin tubes (green top) are used where EDTA would interfere — certain cell-based assays and some mass spectrometry workflows. Heparin is an anticoagulant that works by inhibiting thrombin and other clotting factors. It is not appropriate for DNA-based assays as heparin is a known PCR inhibitor.
Citrate tubes (blue top) are standard for coagulation studies, where preserving the coagulation factor profile is the point. Less commonly used in general biomarker research.
SST / red top tubes are used for serum collection. SST tubes contain a clot activator and gel separator that speeds clotting and simplifies processing. Standard red tops contain no additives and are used when the gel separator would interfere with downstream analysis.
When to Choose Plasma
Plasma is the default choice for most translational research and biomarker discovery applications, and for good reason — it is more analytically consistent, faster to process, and better suited to molecular assays.
- Liquid biopsy (cfDNA, ctDNA) — plasma only; serum is not appropriate because the clotting process degrades cell-free DNA
- Proteomics and multiplex cytokine panels — plasma is generally preferred where an intact, unactivated protein profile is needed; platelet degranulation during serum preparation elevates growth factors and cytokines artificially
- Metabolomics — plasma is preferred; the clotting delay in serum preparation introduces ex vivo metabolic changes
- General biomarker discovery — plasma’s consistency and faster time-to-processing make it the lower-risk default
When to Choose Serum
Serum has real advantages in specific contexts, and for some assay types it is the validated or required matrix.
- Serology and antibody detection — serum is the historical and regulatory standard for antibody titer measurements; many validated immunoassays were developed and cleared using serum, making it the required matrix for comparability
- Autoimmune disease research — disease-specific antibody panels (anti-desmoglein, anti-PLA2R, ANA, RF, anti-CCP) are typically run on serum; this is the dominant matrix in autoimmune biomarker work
- Clinical chemistry analytes — many routine chemistry assays (metabolic panels, lipid panels, thyroid function) are validated for serum; reference ranges are serum-based
- Some ELISA platforms — certain commercial ELISA kits specify serum as the validated matrix; using plasma may require bridging studies to establish comparability
A Practical Decision Framework
| Plasma | Serum | |
| Liquid biopsy (cfDNA/ctDNA) | ✓ Required | ✗ Not appropriate |
| Proteomics / cytokine panels | ✓ Preferred | ⚠ Platelet release confounds some analytes |
| Antibody / serology assays | ⚠ May require bridging | ✓ Preferred or required |
| Autoimmune antibody panels | ⚠ Check assay specs | ✓ Preferred |
| Metabolomics | ✓ Preferred | ⚠ Clotting delay alters metabolite profile |
| Clinical chemistry | ⚠ Check reference ranges | ✓ Standard matrix |
| Time-to-processing sensitivity | Lower (anticoagulant stabilizes) | Higher (clotting window must be controlled) |
The Procurement Implication
Serum and plasma are specified at the point of collection — the tube type determines the output. A biospecimen partner needs to know which matrix your assay requires before a study is designed, not after samples arrive in your lab.
If your program spans multiple assay types — a common scenario in translational research where the same donor cohort feeds both molecular and immunological analyses — it is often worth collecting both matrices in parallel from a single blood draw, provided donor volume allows. This eliminates the need to recollect and ensures case and control specimens are temporally matched across assay platforms.
When in doubt, check your assay kit’s specified matrix before sourcing. If the answer is not clear, it is worth a conversation with your biospecimen partner before locking the collection protocol.
If you are scoping a serum or plasma collection and want to think through the matrix selection, we’d like to hear from you.
MT Group is a biospecimen contract research organization with over 22 years of experience in prospective collection, longitudinal study design, and clinically annotated biospecimen supply. When you need something specific, we’re the group to talk to.
